Silicon Valley Learns to Think Inside the Box

The 23andMe episode seems to suggest that some entrepreneurs, venture capitalists and others around Silicon Valley misunderstand a few things about Washington and the regulatory process. 
Anne Wojcicki and 23andMe learned a costly lesson in how to deal with federal regulators.

Late last year, the Food and Drug Administration decided to take down a rapidly growing Silicon Valley startup called 23andMe Inc., a personal genomics and biotechnology company backed in part by Google Ventures and Russian venture capitalist Yuri Milner. The FDA ordered 23andMe to stop marketing health results from its genetic information product after a lengthy colloquy with the company that (according to the agency) lasted four years and included dozens of meetings, written communications and hundreds of e-mail exchanges.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.